Clinical Trial

A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a phase II single-arm study designed to evaluate the efficacy and safety of P1101 in Chinese PV patients who are intolerance or resistance to HU.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-08-01; most recent amendment 2025-07-30.
Trial Details
NCT Number NCT05485948
Lead Sponsor PharmaEssentia
Conditions Polycythemia Vera
Enrollment 49 participants
Start Date 2021-10-08
Primary Completion 2022-09-07 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2025-08-03